Featured

Novel binder designs mimic TCR specificity for pMCH-I

T cell receptors (TCRs) are highly specific for peptide–MHC (pMHC) complexes, allowing for recognition of specific intracellular antigens, and making them extremely useful in targeting specific target cells. However, TCRs that target specific pMHCs...

Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy

Gong and Luo et al. developed the Cancer Immunology Data Engine (CIDE) using 90 omics datasets with 8,575 profiles from 5,957 patients with 17 solid tumor types. They identified acyloxyacyl hydrolase ...

Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity

Ahn et al. showed in vitro (using human PBMCs) and in mice that IL-10 suppressed IL-2 induction of CRS-associated cytokines by suppressing TNFα production while potentiating IL-2-mediated antitumor ac...

Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer

Huang, Theelen, and Belcaid et al. report the immunomodulatory effects of stereotactic body radiation therapy (SBRT) followed by pembrolizumab in patients with metastatic NSCLC based on a phase 2 tria...

ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy

Murer et al. engineered ANV600 – a novel bispecific antibody–cytokine fusion protein that binds to a non-blocking PD-1 epitope and targets IL-2 to PD-1-expressing cells, without interfering with conco...

See all for this week

Previous Digests

New nanobody bispecific antibody–drug conjugates induced enhanced ICB activity

July 30, 2025

Various approaches have been taken or are underway to improve responses to CTLA-4- or PD-1/PD-L1-directed immune checkpoint blockade (ICB). Making use of nanobodies specific these checkpoints, a nanobody recognizing the murine Ig kappa constant chain (targeting the endogenous antibody...

Meet the newest T cell checkpoint: CD38

July 23, 2025

Immune checkpoint blockade (ICB) can unleash immune responses against a variety of cancers, but its efficacy is often limited by T cell exhaustion. In addition to well established checkpoints like PD-1 and CTLA-4, T cell exhaustion has also been...

Vaccine with ICB sidekick unlock anti-melanoma T cell immunity

July 16, 2025

While personalized neoantigen vaccines have great potential, T cell responses induced by these vaccines often lack strength. Blass, Keskin, et al. aimed to improve T cell antitumor immunity by optimizing vaccine adjuvants and combining the vaccine with ICB. The...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials